#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Breast cancer metastatic Hepatocellular carcinoma Dermatitis atopic Malignant melanoma Non-small cell lung cancer metastatic Type 2 diabetes mellitus Chronic lymphocytic leukaemia More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Glycogen storage disease type I Non-renal cell carcinoma of kidney B-cell lymphoma refractory Gastric cancer Transitional cell cancer of the renal pelvis and ureter CDKL5 deficiency disorder Haemophilia A with anti factor VIII Indolent systemic mastocytosis Fungal infection Pyoderma gangrenosum Hereditary angioedema Cutaneous T-cell lymphoma Drug eruption Hyperchylomicronaemia Cytomegalovirus infection More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma – Treatment Atypical haemolytic uraemic syndrome – Diagnostics Langerhans’ cell histiocytosis – Life with Disease Shprintzen-Goldberg syndrome Paroxysmal nocturnal haemoglobinuria – Trials in Disease Thrombotic thrombocytopenic purpura – Basic Information Richter’s syndrome – Trials in Disease Gastrointestinal stromal tumour – Diagnostics Mucous membrane pemphigoid – Trials in Disease Krabbe’s disease – Life with Disease More diseases…
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Goserelin Mbf-118 Lidocaine Vortioxetine Chlorphenamine Maleate Pantoprazole Amoxicillin Sodium Bempedoic Acid Topiramate Iomeprol Thiotepa Vilobelimab Salbutamol Psma-11 Metolazone Azilsartan Medoxomil Tobramycin Bictegravir Valganciclovir Hydrochloride Pristinamycin More therapies…

    Learn about Your Condition

    Myocarditis Meniere's disease Factor VIII deficiency Osteomyelitis Pulmonary fibrosis Bronchostenosis Tooth loss Alport's syndrome Lymphangioma Pulmonary tuberculosis Medication overuse headache Haematological infection Seizure Round cell liposarcoma Cerebellar ataxia More diseases…
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Sacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    • Buclizine Hydrochloride
    • Codeine Phosphate
    • H2-Receptor Antagonists
    Austria Belgium Bulgaria Denmark Finland France +9

  • A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    • Sacituzumab Tirumotecan
    • Bevacizumab
    Austria Belgium Czechia Denmark Finland France +9

  • Phase 1b-2 Study of Elacestrant and Abemaciclib in Patients with Brain Metastases from ER-Positive, HER2-Negative Breast Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    • Elacestrant
    • Abemaciclib
    Belgium France Germany Greece Italy Spain

  • Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

    Recruiting

    1 1 1 1
    Investigated drugs:
    • Epirubicin
    • Exemestane
    • Paclitaxel Albumin-Bound
    France Germany Italy The Netherlands Spain

  • A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

    Recruiting

    1 1 1
    Investigated drugs:
    • Saruparib
    • Abiraterone Acetate
    Austria Belgium Finland France Germany Hungary +5

  • Study of fianlimab plus cemiplimab with chemotherapy or cemiplimab with chemotherapy for patients with pleural mesothelioma who have not received prior treatment

    Recruiting

    1 1 1
    Investigated diseases:
    • Pleural mesothelioma
    Investigated drugs:
    • Cemiplimab
    • Fianlimab
    France

  • Study of zanidatamab in adult patients with HER2-positive solid tumors (endometrial, colorectal, head & neck, sarcoma) or HER2-mutant non-small cell lung cancer

    Recruiting

    1 1
    Investigated diseases:
    • HER2 mutant non-small cell lung cancer
    • Head and neck cancer
    • Sarcoma
    Investigated drugs:
    • Zanidatamab
    France

  • A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    • Sacituzumab Tirumotecan
    • Vinflunine
    • Docetaxel
    Belgium France Germany Greece Italy The Netherlands +2

  • A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

    Recruiting

    1 1 1 1
    Investigated drugs:
    • Docetaxel
    • Prednisone
    Belgium France Germany Italy Spain

  • Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

    Recruiting

    1 1 1
    Investigated diseases:
    • Hormone-refractory prostate cancer
    Investigated drugs:
    • Lutetium (177Lu) Vipivotide Tetraxetan
    • Gozetotide
    • Piflufolastat (18F)
    France Germany Italy Spain
1 2 3 … 19
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!